Yesterday, we noted that analysts were starting to preview earnings for Valeant Pharmaceuticals International (VRX) despite the fact that it isn’t scheduled to report until May 2. JPMorgan’s Chris Schott, for one, noted that Valeant might beat forecasts but worried that other factors could overwhelm that positive. And today, Wells Fargo’s David Maris added his voice to the mix.
Maris, too writes that Valeant might beat forecasts, but he doesn’t feel the need to change his Underperform rating on the stock, and even dropped his price target to a range of $7 to $9 from a range of $10 to $13. In fact, he writes, “Valeant shares are not worth the risk.” He explains why: